Bio-Path (NASDAQ:BPTH) PT Raised to $40.00 at Roth Mkm

Bio-Path (NASDAQ:BPTH) had its price objective raised by Roth Mkm from $12.00 to $40.00 in a research note published on Wednesday, Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, StockNews.com assumed coverage on Bio-Path in a report on Saturday, March 23rd. They issued a sell rating for the company.

Bio-Path Trading Up 2.0 %

Shares of NASDAQ BPTH opened at $4.12 on Wednesday. The stock has a fifty day simple moving average of $6.91 and a two-hundred day simple moving average of $8.92. Bio-Path has a 1-year low of $3.51 and a 1-year high of $44.80. The firm has a market cap of $2.80 million, a price-to-earnings ratio of -0.10 and a beta of 0.66.

Bio-Path (NASDAQ:BPTH) last posted its quarterly earnings results on Friday, March 8th. The company reported ($5.40) EPS for the quarter, hitting analysts’ consensus estimates of ($5.40). During the same period in the prior year, the business earned ($10.60) earnings per share. Analysts forecast that Bio-Path will post -20.8 EPS for the current year.

Hedge Funds Weigh In On Bio-Path

A number of large investors have recently made changes to their positions in BPTH. Virtu Financial LLC bought a new position in shares of Bio-Path in the first quarter worth $38,000. Renaissance Technologies LLC purchased a new stake in shares of Bio-Path in the second quarter worth $70,000. Citadel Advisors LLC purchased a new stake in shares of Bio-Path in the third quarter worth $35,000. Walleye Capital LLC purchased a new stake in shares of Bio-Path in the third quarter worth $77,000. Finally, Vanguard Group Inc. raised its position in shares of Bio-Path by 77.5% in the fourth quarter. Vanguard Group Inc. now owns 270,029 shares of the company’s stock worth $125,000 after buying an additional 117,914 shares in the last quarter. 5.74% of the stock is owned by institutional investors.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.